DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
RRx-001 is an investigational drug.
There have been 11 clinical trials for RRx-001. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2018.
The most common disease conditions in clinical trials are Lymphoma, Carcinoma, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are EpicentRx, Inc., Drais Pharmaceuticals, Inc., and [disabled in preview].
There are seven US patents protecting this investigational drug and thirty-eight international patents.
Recent Clinical Trials for RRx-001
|RRx-001 Prior to a Platinum Doublet or a Platinum Doublet Alone in Patients With Small Cell Carcinoma||EpicentRx, Inc.||Phase 3|
|Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers||Drais Pharmaceuticals, Inc.||Phase 2|
|Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers||EpicentRx, Inc.||Phase 2|
Top disease conditions for RRx-001
Top clinical trial sponsors for RRx-001
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|RRx-001||Start Trial||Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof||RadioRx, Inc. (Menlo Park, CA) Alliant Techsystems Inc. (Edina, MN)||Start Trial|
|RRx-001||Start Trial||Methods of synthesizing cyclic nitro compounds||Alliant Techsystems Inc. (Minneapolis, MN)||Start Trial|
|RRx-001||Start Trial||Methods of synthesizing cyclic nitro compounds||Alliant Techsystems Inc. (Arlington, VA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|